Chronic obstructive pulmonary disease hospitalization rates in Massachusetts: a trend analysis

Kabir, Zubair; Koh, Howard K.; Clancy, Luke

doi:10.1093/qjmed/hcp190

Cited by 12 publications

(16 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For decades the proportion of daily smokers has been higher in Denmark relative to other developed countries, especially among females [19]. Furthermore, the rate of COPD hospitalisations in Denmark [17] is somewhat higher than in contemporary studies from the USA [20][21][22], Norway, Sweden [23] and France [24]. Hence, compared with other developed countries, the lifetime risk of COPD hospitalisation is probably higher in Denmark.…”

Section: Strengths and Limitationsmentioning

confidence: 99%

Trends in the lifetime risk of COPD exacerbation requiring hospitalisation

et al. 2013

View full text Add to dashboard Cite

This study aimed to estimate time trends in the lifetime risk of hospitalisation with exacerbation of chronic obstructive pulmonary disease (COPD) in Denmark.During the period from 1994 to 2008, a register-based cohort study was conducted covering each subject in the entire population of Denmark (5.18 million in 2008). Based on previously validated diagnosis codes, all COPD hospitalisations were identified. Individual retrospective review periods of 8 years were used to determine first-time hospitalisations. From year 2002 to 2008, all first-time COPD hospitalised subjects aged o30 years were identified. The calculation of lifetime risk was based on age-and sex-specific first-time COPD hospitalisation rates and rates of COPD hospitalisation-free survival, assuming them to be calendar time stationary.The study included 23.9 million person-years of risk time and identified 48 959 first-time COPD hospitalisations. For 30-year-olds in Denmark, the lifetime risk of COPD hospitalisation was 12.0% (95% CI 11.9-12.2) for females and 10.9% (95% CI 10.8-11.1) for males. Trends were generally equal in both sexes.During the period from 2002 to 2008, the rate of first-time COPD hospitalisations decreased, while the survival of never COPD hospitalised subjects increased. In consequence, the lifetime risk of COPD hospitalisation remained constant. @ERSpublications A 10% lifetime risk of COPD hospitalisation remains constant

show abstract

Section: Strengths and Limitationsmentioning

confidence: 99%

Trends in the lifetime risk of COPD exacerbation requiring hospitalisation

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Both small airway disease (obstructive bronchiolitis) and parenchymal destruction lead to chronic airflow limitations in COPD that varies from individual to individual 6. Long-term smoking is the most common risk factor associated with COPD and accounts for 80% to 90% of the cases 7,8. In addition, a current smoker is ten times more likely to die from COPD compared to a non-smoker.…”

Section: Introductionmentioning

confidence: 99%

Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids

Asche¹,

Leader²,

Plauschinat³

et al. 2012

COPD

View full text Add to dashboard Cite

BackgroundTo estimate the potential cost savings by following the current Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline recommendations in patients being treated for chronic obstructive pulmonary disease (COPD) with the combination of long-acting β2-agonist (LABA), long-acting muscarinic antagonist (LAMA) or inhaled corticosteroids (ICS).MethodsThe Geisinger Health System (GHS) database was utilized to identify subjects between January 1, 2004 to March 12, 2007. The index date was based on the first prescription of a LAMA plus LABA, LAMA plus LABA/ICS, or LABA plus ICS. Patients were included in the study if they: had a COPD diagnosis; had data representative of treatment 12 months prior to and 12 months post index date; were 40 years of age or over; had no prior diagnosis for asthma; and had pulmonary function test (PFT) data. We examined the baseline characteristics of these patients along with their healthcare resource utilization. Based on PFT data within 30 days of the index date, a subgroup was classified as adhering or non-adhering to GOLD guidelines.ResultsA total of 364 subjects could be classified as adhering or non-adherent to current GOLD guidelines based on their PFT results. The adherent subgroup received COPD medications consistent with current GOLD guidelines. Of the LAMA plus LABA cohort, 25 patients adhered and 39 patients were non-adherent to current GOLD guidelines. In the cohort of LABA plus ICS, 74 patients were adherent and 180 patients non-adherent to current GOLD guidelines. In the cohort of LAMA plus LABA/ICS, 21 patients were adherent and 25 patients non-adherent to current GOLD guidelines. GOLD adherence was associated with mean total cost of all services savings of $5,889 for LAMA plus LABA, $3,330 for LABA + ICS, and $10,217 for LAMA plus LABA/ICS cohorts.ConclusionStaging of COPD with a PFT and adherence to current GOLD guidelines was associated with lower costs in subjects with moderate to severe COPD. Appropriate use of LAMA plus LABA, LABA plus ICS, and LAMA plus LABA/ICS has economic as well as clinical benefits for patients and payers.

show abstract

“…30 A number of factors may have contributed to the reduction in hospitalization for all respiratory causes among COPD patients. First, the use of longacting beta agonists with corticosteroids, which increased after the release of combination long-acting beta agonists and corticosteroids in 2000, and the release of Global Initiatives for Chronic Obstructive Lung Disease guidelines in 2001 may have helped reduce the rate of acute exacerbations of COPD.…”

Section: Discussionmentioning

confidence: 99%

Temporal Trends in Hospitalization Rates for Older Adults with Chronic Obstructive Pulmonary Disease

Baillargeon

Wang

Kuo

et al. 2013

The American Journal of Medicine

View full text Add to dashboard Cite

BACKGROUND Over the last 15 years, substantial advances have been made in the treatment of chronic obstructive pulmonary disease (COPD). Little information is available, however, on whether these treatments have resulted in reduced rates of hospitalization and acute exacerbations among COPD patients. This retrospective cohort study examined changes in hospitalization rates among Medicare beneficiaries with COPD from 1999 to 2008. METHODS We analyzed data from 424,418 fee-for-service Medicare beneficiaries enrolled between 1999 and 2008 who were diagnosed with COPD. We examined temporal changes in the frequency of hospitalization and acute exacerbations among Medicare beneficiaries with COPD. RESULTS Over the 10-year study period, the hospitalization rates for COPD patients—adjusted for age, sex, race, socioeconomic status, region, and number of comorbidities—decreased: from 131 to 107 per 100 person-years for all causes (P < .001); from 58 to 44 per 100 person-years for all respiratory causes (P < .001); and from 73 to 63 per 100 person-years for nonrespiratory causes (P < .001). There was no change in prevalence of COPD in the Medicare population over this time. Additionally, the percentage of COPD patients hospitalized with 2 or more acute exacerbations decreased from 5.5% to 4.3% over the 10-year study period (P < .001). CONCLUSION Between 1999 and 2008, hospitalization rates decreased substantially among Medicare beneficiaries diagnosed with COPD.

show abstract

Chronic obstructive pulmonary disease hospitalization rates in Massachusetts: a trend analysis

Cited by 12 publications

References 15 publications

Trends in the lifetime risk of COPD exacerbation requiring hospitalisation

Trends in the lifetime risk of COPD exacerbation requiring hospitalisation

Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids

Temporal Trends in Hospitalization Rates for Older Adults with Chronic Obstructive Pulmonary Disease

Contact Info

Product

Resources

About